 |
5 Products |  |
33 Diseases | | 5 Products |
|
1369 Trials |  |
5508 News |  |
| «12...4567891011121314...4748» |
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal, Metastases: Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study. (Pubmed Central) - Feb 6, 2024
Anlotinib plus PD-1 blockades demonstrated encouraging efficacy and acceptable safety profile in patients with treatment-refractory metastatic CRC preliminarily in clinical practice. This conclusion should be confirmed in prospective clinical trials.
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Case report of radiotherapy combined with anlotinib and immunotherapy for a patient with esophageal cancer and esophageal fistula. (Pubmed Central) - Feb 5, 2024
This conclusion should be confirmed in prospective clinical trials. After radiation therapy, the patient continued to be treated with anlotinib and immunotherapy with camrelizumab, and the patient's lesion improved.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Astragaloside IV Overcomes Anlotinib Resistance in Non-small Cell Lung Cancer through miR-181a-3p/UPR-ERAD Axis. (Pubmed Central) - Feb 4, 2024
After radiation therapy, the patient continued to be treated with anlotinib and immunotherapy with camrelizumab, and the patient's lesion improved. This research revealed a promising NSCLC/AR treatment approach by showing that AS-IV exposed NSCLC cells to anlotinib by inhibiting the miR-181a-3p/UPR-ERAD axis.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib + penpulimab plus chemo-less therapy in first-line treatment for persistent, recurrent, or metastatic cervical cancer: a single-arm, phase ? study (ALTN-AK105-II-06) () - Feb 3, 2024 - Abstract #SGO2024SGO_773;
- Focus V (anlotinib) / Advenchen, Sino Biopharm
The efficacy and safety of combining anlotinib with albumin-bound paclitaxel and cisplatin in patients with recurrent advanced cervical cancer: A prospective single-arm, open-label, phase II trial () - Feb 3, 2024 - Abstract #SGO2024SGO_625;
- Kaitanni (cadonilimab) / Akesobio, Focus V (anlotinib) / Advenchen, Sino Biopharm
A prospective, single-arm, open-label phase II clinical trial on efficacy and safety of Cadonilimab plus Anlotinib for Recurrent, Metastasis or Persistent Cervical Cancer () - Feb 3, 2024 - Abstract #SGO2024SGO_576;
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Monotherapy, Metastases: Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy. (Pubmed Central) - Jan 31, 2024
This research revealed a promising NSCLC/AR treatment approach by showing that AS-IV exposed NSCLC cells to anlotinib by inhibiting the miR-181a-3p/UPR-ERAD axis. Our research suggested that anlotinib and gemcitabine-based chemotherapy showed similar clinical efficacy and safety in the subsequent treatment of advanced STS after the failure of anthracycline-based chemotherapy.
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
New P2 trial: Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA (clinicaltrials.gov) - Jan 25, 2024
P2, N=90, Not yet recruiting, Sponsor: Peking University
- | Tyvyt (sintilimab) / Innovent Biologics, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: PRIORITY: Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 24, 2024
P2, N=30, Not yet recruiting, Sponsor: Ningbo No.2 Hospital
- || Focus V (anlotinib) / Advenchen, Sino Biopharm, Sutent (sunitinib) / Pfizer
Review, Journal: Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection. (Pubmed Central) - Jan 23, 2024
Although heterogeneity in liposarcoma genetics and phenotype as well as the associated development of resistance to therapy make difficult the introduction of novel therapeutic targets into the clinic, recently a number of targeted therapy drugs were proposed for LPS treatment. The most promising results were shown for CDK4/6 and MDM2 inhibitors as well as for the multi-kinase inhibitors anlotinib and sunitinib.
- ||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm, TQB2618 / Sino Biopharm
Enrollment open, Trial initiation date, Monotherapy, Metastases: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection (clinicaltrials.gov) - Jan 23, 2024
P1, N=75, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The most promising results were shown for CDK4/6 and MDM2 inhibitors as well as for the multi-kinase inhibitors anlotinib and sunitinib. Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Jan 2024
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date: NeoATCT: A Phase ? Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer (clinicaltrials.gov) - Jan 22, 2024
P2, N=32, Recruiting, Sponsor: Sichuan Provincial People's Hospital
Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Jan 2024 Trial completion date: Jul 2023 --> Sep 2025 | Trial primary completion date: Jul 2022 --> Mar 2025
- Three-Dimensional Bioprinting Model Of Ovarian Cancer For Identification Of Patient-Specific Therapy Response (Session hall III (112)) - Jan 18, 2024 - Abstract #ESGO2024ESGO_479;
3DP-OC demonstrated diverse drug responses, underlining its potential for precision medicine. Our ongoing research aims to correlate 3DP-OC drug responses with clinical outcomes.
- | Tevimbra (tislelizumab) / BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma (clinicaltrials.gov) - Jan 17, 2024
P2, N=66, Recruiting, Sponsor: Fudan University
- | Retrospective data, Journal, Metastases: Small molecule multitarget antiangiogenic inhibitor treatments for advanced thymic epithelial tumors: A retrospective study. (Pubmed Central) - Jan 16, 2024
Our ongoing research aims to correlate 3DP-OC drug responses with clinical outcomes. The findings suggest that small molecule multitarget antiangiogenic inhibitors are efficacious as second or post-line treatments as a viable alternative treatment option for patients with advanced TETs.
- || Loqtorzi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer. (Pubmed Central) - Jan 15, 2024
In patients with advanced BTC, the combination of anlotinib and toripalimab demonstrated remarkable anti-tumor potential, with increased objective response rates (ORR), longer overall survival (OS) and progression-free survival (PFS). Moreover, STK11 and CD8/Foxp3 may be as biomarkers that can predict the
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non-small-cell lung cancer. (Pubmed Central) - Jan 14, 2024
By investigating the effects of using both anlotinib and PD-1/PD-L1 inhibitors, this study enhances our understanding of lipid metabolism in lung cancer treatment. The findings from this research provide valuable insights into potential therapeutic approaches and the identification of new therapeutic biomarkers.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker: In Situ Nanofiber Patch Boosts Postoperative Hepatocellular Carcinoma Immune Activation by Trimodal Combination Therapy. (Pubmed Central) - Jan 11, 2024
Herein, a portable nanofiber patch composing germanium phosphorus (GeP) and anlotinib (AL) was designed to form a versatile platform for molecularly targeted photothermal-immune checkpoint blockade (ICB) trimodal combination therapy...Further validation of the genome sequencing results revealed cell pathways related primarily to regulatory immune effects. This study demonstrates the use of an effective and practical nanofiber patch to improve multimodal therapy of postoperative HCC, with high clinical translation value.
- || Tevimbra (tislelizumab) / BeiGene, Keytruda (pembrolizumab) / Merck (MSD), Focus V (anlotinib) / Advenchen, Sino Biopharm
Review, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature. (Pubmed Central) - Jan 9, 2024
In advanced pancreatic cancer, a prognosis of this magnitude is rare. Our cases reveal the potential of immunotherapy as a cornerstone treatment in the management of advanced pancreatic cancer.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Preclinical, Journal: Reduction of acute radiation-induced brain injury in rats by anlotinib. (Pubmed Central) - Jan 8, 2024
Our cases reveal the potential of immunotherapy as a cornerstone treatment in the management of advanced pancreatic cancer. This study found that anlotinib has a protective effect against RBI in rats and anlotinib may be a new candidate for the treatment of RBI.
- | New P4 trial, Real-world evidence, Real-world, Metastases: A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer (clinicaltrials.gov) - Jan 8, 2024
P4, N=200, Recruiting, Sponsor: Fudan University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Tumor mutational burden, PARP Biomarker: Anlotinib suppresses the DNA damage response by disrupting SETD1A and inducing p53-dependent apoptosis in Transformed Follicular Lymphoma. (Pubmed Central) - Jan 6, 2024
Furthermore, anlotinib greatly downregulated the antiapoptotic proteins Mcl-1 and in parallel upregulated the proapoptotic element BAX and Bak, accompanied by caspase-3 activation and PARP degradation. Anlotinib has a good proapoptotic effect on tumor cells in vitro and in vivo, and its possible mechanism is related to the inhibition of the DNA damage response by disrupting SETD1A.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010) (Hall F) - Jan 3, 2024 - Abstract #SGO2024SGO_91;
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Avastin (bevacizumab) / Roche
Enrollment change, Trial completion date, Trial primary completion date, Metastases: GASTO-1086: Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab (clinicaltrials.gov) - Jan 3, 2024
P2, N=116, Recruiting, Sponsor: Sun Yat-sen University
Anlotinib has a good proapoptotic effect on tumor cells in vitro and in vivo, and its possible mechanism is related to the inhibition of the DNA damage response by disrupting SETD1A. N=60 --> 116 | Trial completion date: Feb 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Dec 2024
- | Benlysta (belimumab) / GSK, Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial, Metastases: The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study (clinicaltrials.gov) - Jan 2, 2024
P=N/A, N=30, Recruiting, Sponsor: Ningbo Medical Center Lihuili Hospital
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Penpulimab combined with anlotinib in patients with R/M HNSCC after failure of platinum-based chemotherapy: a single-arm, multicenter, phase ? study. (Pubmed Central) - Jan 2, 2024
N=60 --> 116 | Trial completion date: Feb 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Dec 2024 Penpulimab combined with anlotinib demonstrated promising efficacy and manageable safety in R/M HNSCC patients after failure of platinum-based chemotherapy.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Aurora-A inhibitor synergistically enhances the inhibitory effect of anlotinib on hepatocellular carcinoma. (Pubmed Central) - Jan 2, 2024
Penpulimab combined with anlotinib demonstrated promising efficacy and manageable safety in R/M HNSCC patients after failure of platinum-based chemotherapy. In summary, we have demonstrated the effectiveness of combining anlotinib with an Aurora-A inhibitor, which expands the potential applications of anlotinib in the clinical treatment of HCC in the future.
- | Tyvyt (sintilimab) / Innovent Biologics, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Phase classification, Trial completion date: Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC (clinicaltrials.gov) - Jan 2, 2024
P2, N=45, Active, not recruiting, Sponsor: Tang-Du Hospital
In summary, we have demonstrated the effectiveness of combining anlotinib with an Aurora-A inhibitor, which expands the potential applications of anlotinib in the clinical treatment of HCC in the future. Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P2 | Trial completion date: Dec 2023 --> Dec 2026
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial primary completion date, Metastases: DRAGON - IV: Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer (clinicaltrials.gov) - Dec 31, 2023
P2/3, N=580, Active, not recruiting, Sponsor: Ruijin Hospital
- | sunvozertinib (DZD9008) / Dizal Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: WUKONG-9: A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Dec 27, 2023
P2, N=45, Not yet recruiting, Sponsor: Shanghai Zhongshan Hospital
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Metastases: ALTER-GO-020: A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer (clinicaltrials.gov) - Dec 27, 2023
P2, N=86, Recruiting, Sponsor: Sichuan Cancer Hospital and Research Institute
Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P2 | Trial completion date: Dec 2023 --> Dec 2026 Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Metastases: Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study (clinicaltrials.gov) - Dec 27, 2023
P2, N=43, Recruiting, Sponsor: Yongchang Zhang
Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
- | Rozlytrek (entrectinib) / Roche
Journal, PD(L)-1 Biomarker: Case report: Successful sequential therapy of crizotinb and entrectinib in ROS1-positive non-small-cell lung cancer with brain metastasis in later-settings. (Pubmed Central) - Dec 26, 2023
A ROS1-rearranged NSCLC with CNS metastases responded to sequential tyrosine kinase inhibitors treatment of crizotinb followed by entrectinib. This report has potential implications in guiding decisions for the treatment after crizotinib resistance.
- || Imfinzi (durvalumab) / AstraZeneca
P2 data, Journal: Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive-stage small-cell lung cancer patients (DURABLE study). (Pubmed Central) - Dec 21, 2023
This report has potential implications in guiding decisions for the treatment after crizotinib resistance. We conduct a phase II study to investigate the safety and efficacy of durvalumab combined with anlotinib as maintenance treatment in ES-SCLC patients.
- || Kaitanni (cadonilimab) / Akesobio, Focus V (anlotinib) / Advenchen, Sino Biopharm
P1/2 data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer. (Pubmed Central) - Dec 19, 2023
P1/2
We conduct a phase II study to investigate the safety and efficacy of durvalumab combined with anlotinib as maintenance treatment in ES-SCLC patients. Cadonilimab 10?mg/kg Q3W plus anlotinib showed manageable safety and promising efficacy as a first-line chemo-free treatment for advanced NSCLC.
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, PD(L)-1 Biomarker, IO biomarker: Multi-targeted tyrosine kinase inhibitor reverses resistance to immunotherapy in hepatic sarcomatoid carcinoma. (Pubmed Central) - Dec 18, 2023
Cadonilimab 10?mg/kg Q3W plus anlotinib showed manageable safety and promising efficacy as a first-line chemo-free treatment for advanced NSCLC. Following this regimen, a synergistic treatment approach comprising both anlotinib and sintilimab was instituted, culminating in an ensuing 11
- || Review, Journal: An Overview of the Use of Anti-Angiogenic Agents in the Treatment of Thymic Epithelial Tumors. (Pubmed Central) - Dec 17, 2023
The current evidence suggests that the most active agent is lenvatinib, whereas sunitinib could be proposed as an acceptable second-line therapy for TC. Further research concerning the combination of immune checkpoint inhibitors with anti-angiogenic drugs is warranted.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, P2 data, Retrospective data, Journal: Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double-blind phase 2 study. (Pubmed Central) - Dec 13, 2023
The most common grade 3 or higher AEs were increased lipase (19.0%), hypertension (14.3%), and hyponatremia (14.3%) in the anlotinib group. Anlotinib proved to have potential CNS activity and a manageable toxicity profile in patients with SCLC and BM, significantly delaying CNS progression.
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Application of sintilimab combined with anlotinib hydrochloride in the clinical treatment of microsatellite stable colorectal cancer. (Pubmed Central) - Dec 11, 2023
The combination of sintilimab and anlotinib hydrochloride demonstrated favorable efficacy in the treatment of MSS CRC patients, leading to improvements in patient immunity and prognosis. Additionally, it exerted inhibitory effects on the expression of carcinoembryonic antigen, CA199, and CA125.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal: Anlotinib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma associated with hepatitis B virus: a retrospective controlled study. (Pubmed Central) - Dec 11, 2023
In addition, this combination therapy has demonstrated a controllable safety profile. However, further validation is urgently needed through randomized controlled trials with large sample sizes.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Trial completion date, Metastases: Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL) (clinicaltrials.gov) - Dec 11, 2023
P2, N=40, Active, not recruiting, Sponsor: Sun Yat-sen University
However, further validation is urgently needed through randomized controlled trials with large sample sizes. Recruiting --> Active, not recruiting | Trial completion date: Aug 2028 --> Oct 2026
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma (clinicaltrials.gov) - Dec 11, 2023
P2, N=68, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- TQB2858 / Sino Biopharm
Enrollment change, Trial termination, IO biomarker, Metastases: A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma (clinicaltrials.gov) - Dec 8, 2023
P1, N=29, Terminated, Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Recruiting --> Active, not recruiting | Trial completion date: Aug 2028 --> Oct 2026 N=104 --> 29 | Recruiting --> Terminated; Terminated due to the adjustment of sponsor's development strategies and pipeline.
- ||| Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC) (clinicaltrials.gov) - Dec 7, 2023
P4, N=600, Not yet recruiting, Sponsor: Fudan University
N=104 --> 29 | Recruiting --> Terminated; Terminated due to the adjustment of sponsor's development strategies and pipeline. N=60 --> 600 | Trial completion date: Mar 2025 --> Jan 2027 | Initiation date: Aug 2023 --> Nov 2023 | Trial primary completion date: Jan 2025 --> Sep 2025
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P2 trial: Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi (clinicaltrials.gov) - Dec 7, 2023
P2, N=80, Not yet recruiting, Sponsor: Guangxi Medical University
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Updated survival results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer. (Level 1, West Hall; Poster Bd # H16) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_777;
P2
Anlotinib combined with oxaliplatin and capecitabine achieved considerable OS and showed potential efficacy as first-line therapy for mCRC with manageable toxicity profiles. Clinical trial information: NCT04080843.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from multi-cohort, multi-center phase II trial ALTER-G-001-cohort A. (Level 1, West Hall; Poster Bd # G16) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_758;
P2
Anlotinib plus chemotherapy as first-line treatment has shown promising efficacy and acceptable safety and maybe a favorable option for advanced LMs CRC tumors. Clinical trial information: NCT05262335.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C. (Poster Bd # L2) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_569;
P2
Anlotinib plus chemotherapy as first-line treatment has shown promising efficacy and acceptable safety and maybe a favorable option for advanced LMs GI tumors, especially for pancreatic cancer. Clinical trial information: NCT05262335.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Update results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery: A single arm, multi-center, phase II clinical trial. (Poster Bd # D20) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_455;
P2
And the conclusions needed to be confirmed in large scale clinical trials subsequently. Clinical trial information: NCT04213118.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial. (Poster Bd # D5) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_441;
P2
The conclusion should be validated in more patients consecutively. Clinical trial information: NCT05812430.